Invesco’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-39,106
| Closed | -$1.5M | – | 3949 |
|
|
2023
Q2 | $1.5M | Buy |
39,106
+1,368
| +4% | +$35.1K | ﹤0.01% | 2727 |
|
|
2023
Q1 | $874K | Sell |
37,738
-170,794
| -82% | -$4.07M | ﹤0.01% | 2957 |
|
|
2022
Q4 | $5.46M | Buy |
208,532
+13,422
| +7% | +$297K | ﹤0.01% | 2205 |
|
|
2022
Q3 | $3.83M | Sell |
195,110
-151,544
| -44% | -$3.04M | ﹤0.01% | 2355 |
|
|
2022
Q2 | $6.06M | Buy |
346,654
+315,755
| +1,022% | +$4.96M | ﹤0.01% | 2174 |
|
|
2022
Q1 | $506K | Buy |
30,899
+19,852
| +180% | +$270K | ﹤0.01% | 3382 |
|
|
2021
Q4 | $180K | Sell |
11,047
-945
| -8% | -$13.5K | ﹤0.01% | 3808 |
|
|
2021
Q3 | $153K | Buy |
11,992
+1,512
| +14% | +$19.9K | ﹤0.01% | 3867 |
|
|
2021
Q2 | $148K | Buy |
+10,480
| New | +$168K | ﹤0.01% | 3840 |
|
|
2020
Q1 | – | Sell |
-10,867
| Closed | -$64K | – | 3751 |
|
|
2019
Q4 | $64K | Sell |
10,867
-720
| -6% | -$3.91K | ﹤0.01% | 3625 |
|
|
2019
Q3 | $61K | Sell |
11,587
-460
| -4% | -$3.05K | ﹤0.01% | 3643 |
|
|
2019
Q2 | $93K | Sell |
12,047
-414
| -3% | -$6.3K | ﹤0.01% | 3683 |
|
|
2019
Q1 | $248K | Buy |
+12,461
| New | +$217K | ﹤0.01% | 3561 |
|
|
2016
Q3 | – | Sell |
-10,127
| Closed | -$573K | – | 3689 |
|
|
2016
Q2 | $573K | Buy |
+10,127
| New | +$615K | ﹤0.01% | 3174 |
|
|
2015
Q3 | – | Sell |
-30
| Closed | -$5K | – | 4053 |
|
|
2015
Q2 | $5K | Buy |
+30
| New | +$4.95K | ﹤0.01% | 4233 |
|
Invesco's KDNY Position: Q3 2023 in Review
Invesco sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 39,106 shares — an estimated $1.5M sold.
Invesco first reported a position in KDNY in Q2 2015 and held it in 15 quarters. The position peaked at $6.06M in Q2 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Invesco reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Invesco sold 39,106 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.5M.
- Invesco first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 15 quarters.
- Invesco's Chinook Therapeutics, Inc. Common Stock position peaked at $6.06M in Q2 2022.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Invesco's 13F filing for Q3 2023, filed 13 Nov 2023.